AI can help healthcare organizations (HCOs) identify individuals at-risk for developing Metabolic syndrome (MetS).
Metabolic syndrome (MetS) is a clustering of risk factors, including central obesity, insulin resistance, dyslipidemia, and hypertension that increases the risk of cardiovascular disease threefold and the risk of type 2 diabetes fivefold (1). People with MetS also often have other conditions, including excessive blood clotting and constant, low-grade inflammation throughout the body. MetS has also been associated with a plethora of cancers including breast, pancreatic, colon and liver cancer (2,3).
Nearly one-third of U.S. adults—approximately 80 million people—meet the criteria for MetS (1). Such a high prevalence and potential for adverse outcomes imposes an enormous clinical and economic burden. Healthcare costs for individuals with MetS are 60% higher, and increase by another 24% for each additional risk factor (4). In total, the annual healthcare costs for people with MetS is estimated to exceed $220 billion (5). And yet, public awareness of MetS is alarmingly low. In a study of people with diabetes or at elevated risk for developing it, less than 15% indicated they had heard of the condition (6). Increased awareness and identification is paramount; an additional 104 million people are at risk for developing MetS (1).
Fortunately, MetS is preventable and potentially reversible, but success depends on the ability to better identify people at risk for MetS and to individually-tailor medical treatments and health interventions that can improve outcomes. AI can help healthcare organizations (HCOs) identify individuals at-risk for developing MetS and provide critical insight into their specific risk factors. Predictive analytics can enable care teams to personalize interventions with self-management support, diet and exercise regimes, and greater continuity of care.